Stocktoria
PRECIGEN, INC. PGEN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-08-08
PRECIGEN, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.7M | $3.9M | $6.2M | $26.9M | $14.3M |
| R&D expense | $41.3M | $53.1M | $48.6M | — | — |
| SG&A expense | $70.1M | $41.3M | $40.4M | — | — |
| Operating income | -$110.5M | -$135.0M | -$99.8M | — | — |
| Income tax | $3,000 | -$1.8M | -$458,000 | -$189,000 | -$160,000 |
| Net income | -$250.6M | -$126.2M | -$95.9M | $28.3M | -$92.2M |
| EPS (diluted) | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 |
| Operating cash flow | -$87.8M | -$68.2M | -$66.9M | -$65.0M | -$55.8M |
| Free cash flow | -$89.8M | -$76.8M | -$68.5M | -$70.0M | -$63.0M |
| Cash & equivalents | $30.2M | $29.5M | $7.6M | $4.9M | $36.4M |
| Total assets | $155.5M | $145.3M | $151.0M | $216.0M | $359.9M |
| Total liabilities | $134.6M | $78.5M | $32.5M | $89.7M | $252.5M |
| Shareholders' equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.3M |
Source: SEC EDGAR filings · CIK 0001356090 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.